Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05839600 · ClinicalTrials.gov registry record · Phase 1
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05839600 is a Phase 1 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 10 participants.
The verdict
NCT05839600, a Phase 1 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part. The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer. In this study, BI 1821736 is given to humans for the first time. Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by BI 1821736.
Interventions
- DRUG BI 1821736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2025-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05839600
The ClinicalTrials.gov registry entry for NCT05839600 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 1821736 is the first listed.
NCT05839600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05839600 about?
NCT05839600 is a clinical study titled "A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer". This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part. The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can ...
What is the current status of trial NCT05839600?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-06-07. Estimated completion is 2025-04-10.
What interventions are being tested in trial NCT05839600?
The interventions under investigation include: BI 1821736 (DRUG).
Who is sponsoring clinical trial NCT05839600?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.